

Raptor Pharmaceutical Corp  
Form 8-K  
June 17, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 15, 2010**

**RAPTOR PHARMACEUTICAL CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**

**000-25571**

**86-0883978**

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

**9 Commercial Blvd., Suite 200, Novato, California**

**94949**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(415) 382-8111**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On June 15, 2010, Raptor Pharmaceutical Corp., a Delaware corporation (the Company), issued a press release announcing the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion recommending orphan medicinal product designation for DR Cysteamine for the potential treatment of cystinosis, which would allow the Company to have ten years of market exclusivity in the European Union once the drug is approved as a treatment for cystinosis.

The Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Exhibit Description</b>	<b>Filed Here with</b>	<b>Form</b>	<b>File No.</b>	<b>Incorporated by Reference</b>		
					<b>Exhibit</b>	<b>Filing Date</b>	<b>Filed By</b>
99.1	Press release issued by the Company dated as of June 15, 2010	X					

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**RAPTOR PHARMACEUTICAL CORP.**

Date: June 16, 2010

By: /s/ Kim R. Tsuchimoto  
Name: Kim R. Tsuchimoto  
Title: Chief Financial Officer, Treasurer and  
Secretary

---

**Exhibit Index**

<b>Exhibit No.</b>	<b>Exhibit Description</b>	<b>Filed Here with</b>	<b>Form</b>	<b>Incorporated by Reference</b>			<b>Filed By</b>
		<b>with</b>		<b>File No.</b>	<b>Exhibit</b>	<b>Filing Date</b>	
99.1	Press release issued by the Company dated as of June 15, 2010	X					